[144] Crinetics Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Crinetics Pharmaceuticals (CRNX) filed a Form 144 disclosing a proposed sale of 30,000 shares of Common stock through Morgan Stanley Smith Barney with an aggregate market value of $882,000, to be sold on 08/22/2025 on NASDAQ. The shares were reported acquired that same day on 08/22/2025 by exercise of stock options from the issuer, with cash payment reported for the option exercise.

The filing also lists prior 10b5-1 sales by Dana Pizzuti of 6,492 shares on 08/20/2025 generating gross proceeds of $189,426.82. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Clear compliance disclosure under Rule 144 showing planned sale details (shares, broker, market value, exchange).
• Immediate disclosure of both the option exercise and intended sale date, supporting transparency.

Negative

• Insider liquidity event: 30,000-share sale may be perceived negatively by some investors as insider selling.
• Concentrated sale timing: Acquisition and planned sale occur on the same date, indicating no extended holding period.

Insights

Securities Analyst

TL;DR: Insider exercised options and plans to sell 30,000 shares for $882k; recent 10b5-1 sale of 6,492 shares netted $189k.

The filing documents a routine Rule 144 notice following an option exercise on the same day as the planned sale, indicating immediate disposition rather than a long-term hold. Use of Morgan Stanley Smith Barney and an explicitly stated cash payment for exercise are consistent with standard execution and brokerage arrangements. Prior 10b5-1 sales by the named seller are disclosed, showing recent liquidity activity.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 requirements; seller affirms no undisclosed material information and references 10b5-1 activity.

The form contains required attestations about material information and references a prior trading plan execution (10b5-1) for recent sales. From a governance perspective, timely public disclosure of planned insider sales supports regulatory compliance and market transparency.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30000	882000.00	94175994	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Exercise of Stock Options	Issuer			30000	08/22/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	08/20/2025	6492	189426.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Crinetics (CRNX) report in this Form 144?

The filing reports a proposed sale of 30,000 common shares with an aggregate market value of $882,000, to be sold on 08/22/2025 on NASDAQ.

How were the 30,000 shares acquired?

The shares were acquired on 08/22/2025 by exercise of stock options from the issuer, with payment in cash.

Who is the broker handling the sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC, New York.

Were there any recent sales by the same person?

Yes. The filing discloses a prior 10b5-1 sale by Dana Pizzuti of 6,492 shares on 08/20/2025 for gross proceeds of $189,426.82.

Does the seller assert they possess undisclosed material information?

The notice includes the seller's representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.